Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Current vaccine adjuvants: an overview of a diverse class.

Literature DB >> 15353330

Current vaccine adjuvants: an overview of a diverse class.

Charlotte Read Kensil¹, Annie Xiaoyan Mo, Alemseged Truneh.

Abstract

Numerous compounds are under evaluation as immunological adjuvants for improvement of vaccine performance. This review will briefly summarize some of the many diverse substances that are currently being utilized as vaccine adjuvants in preclinical and clinical studies.

Mesh：

Substances：

Year: 2004 PMID： 15353330 DOI： 10.2741/1452

Source DB: PubMed Journal: Front Biosci ISSN： 1093-4715

Keyword Cloud
Cited

13 in total

Review 1. Liposome-nucleic acid immunotherapeutics.

Authors: Steven Dow
Journal: Expert Opin Drug Deliv Date: 2008-01 Impact factor: 6.648

2. Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells.

Authors: Giang H Pham; Bibiana V Iglesias; Edmund J Gosselin
Journal: Vaccine Date: 2014-07-26 Impact factor: 3.641

3. Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide.

Authors: Pengfei Wang; Dattatray A Devalankar; Qipu Dai; Ping Zhang; Suzanne M Michalek
Journal: J Org Chem Date: 2016-10-13 Impact factor: 4.354

4. Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.

Authors: Angela Henderson; Katie Propst; Ross Kedl; Steven Dow
Journal: Vaccine Date: 2011-05-19 Impact factor: 3.641

5. Analysis of novel meningococcal vaccine formulations.

Authors: Susu M Zughaier
Journal: Hum Vaccin Immunother Date: 2017-04-10 Impact factor: 3.452

6. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice.

Authors: Mohammad Ali Danesh-Bahreini; Javad Shokri; Afshin Samiei; Eskandar Kamali-Sarvestani; Mohammad Barzegar-Jalali; Soliman Mohammadi-Samani
Journal: Int J Nanomedicine Date: 2011-04-20

Current vaccine adjuvants: an overview of a diverse class.

Review 1. Liposome-nucleic acid immunotherapeutics.

2. Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells.

3. Synthesis and Evaluation of QS-21-Based Immunoadjuvants with a Terminal-Functionalized Side Chain Incorporated in the West Wing Trisaccharide.

4. Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.

5. Analysis of novel meningococcal vaccine formulations.

6. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice.

7. Synthesis of QS-21-based immunoadjuvants.

8. Vaccine Adjuvants Derivatized from Momordica Saponins I and II.

9. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.

10. Structural Effect on Adjuvanticity of Saponins.